These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22294367)

  • 1. Studies on hepatitis C virus resistance to inhibitors in replicon systems.
    Zhao Y; Huang M
    Curr Protoc Pharmacol; 2010 Sep; Chapter 13():Unit 13B.2. PubMed ID: 22294367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of compound activity against hepatitis C virus in replicon systems.
    Yang G; Huang M
    Curr Protoc Pharmacol; 2010 Sep; Chapter 13():Unit 13B.1. PubMed ID: 22294366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.
    Mo H
    Curr Protoc Pharmacol; 2011 Jun; Chapter 13():Unit 13B.5. PubMed ID: 21935899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
    Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
    Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting and characterizing drug-resistant hepatitis C virus replicon.
    Vliegen I; Delang L; Neyts J
    Methods Mol Biol; 2013; 1030():93-103. PubMed ID: 23821262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
    Pfeiffer JK; Kirkegaard K
    J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
    Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
    Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
    Hao W; Duggal R
    Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells.
    Naka K; Abe K; Takemoto K; Dansako H; Ikeda M; Shimotohno K; Kato N
    J Hepatol; 2006 May; 44(5):869-78. PubMed ID: 16545484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication.
    Lin HM; Wu PS; Hu HS; Chang WC; Wu RH; Tian JN; Chern JH; Yueh A
    J Virol Methods; 2018 Sep; 259():10-17. PubMed ID: 29782889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.